SPH4336

DRUG2 trials

Sponsors

Shanghai Pharma Biotherapeutics USA Inc., Shanghai Pharmaceuticals Holding Co., Ltd

Conditions

Advanced Solid TumorsLiposarcoma, Dedifferentiated

Phase 1

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

RecruitingNCT05944224

Shanghai Pharmaceuticals Holding Co., LtdAdvanced Solid Tumors

Start: 2023-10-17End: 2026-12-31Target: 63Updated: 2026-08-06

Phase 2

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

TerminatedNCT05580588

Shanghai Pharma Biotherapeutics USA Inc.Liposarcoma, Dedifferentiated

Start: 2023-08-31End: 2024-10-31Updated: 2025-06-13

Related Papers

Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors

The Oncologist2025-06-01